This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Stocks in Motion

Updated from 2:59 p.m. EDT

Shares of Dyax (DYAX - Get Report) were among the worst-performing health and pharmaceutical stocks Friday, falling 24.7% after the company posted mixed third-quarter financial results and provided guidance on its DX-88 drug program.

The biotherapeutics company posted a third-quarter loss of 25 cents a share on sales of $3.3 million. Analysts polled by Thomson First Call were expecting a loss of 27 cents a share on sales of $4.6 million. A year ago, the company posted a loss of 25 cents a share on sales of $5.9 million.

In addition to its earnings announcement, Dyax also said it expects to file a biologics license application for its hereditary angioedema drug with the Food and Drug Administration some time after 2005. Dyax and its partner, Genzyme (GENZ), are in "ongoing discussions with the agency to plan additional clinical work that will be required" before it files its application. Dyax said it remains confident that it can advance DX-88 to the commercialization stage. Earlier this month the drug received fast-track designation from the FDA. Shares traded down $1.99 to $6.08.

McKesson (MCK - Get Report) rose 8.7% after the drug wholesaler turned in second-quarter earnings results that were better than expected. The company earned 29 cents a share on a 19% jump in sales, which came in at $19.9 billion. Analysts were expecting earnings of 24 cents a share during the quarter. A new agreement with the Department of Veteran Affairs, the acquisition of AdvancePCS, and strength in its Canadian business accounted for the strong sales results during the quarter.

Looking ahead, McKesson expects full-year earnings of $2 to $2.20 a share, down from previous guidance of $2.20 to $2.35 a share, which it issued just last month. Analysts are expecting earnings of $2.09 a share. Shares traded up $2 to $24.98.

Shares of Iridex (IRIX - Get Report) fell 37% after the company announced that its laser treatment for age-related blindness did not demonstrate a significant difference compared to a placebo. The company said that 47% of patients treated with its Transpupillary Thermotherapy laser treatment avoided modest or severe vision loss compared to 43% who did not use the treatment. Iridex said the difference between the two was "not statistically significant." Shares traded down $2.64 to $4.50.

Gilead Sciences (GILD - Get Report) fell 9.4% after the company posted third-quarter earnings results. The biopharmaceutical company earned 25 cents a share during the quarter on sales of $326.2 million. Analysts were expecting earnings of 21 cents a share on sales of $318.7 million.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ELN $0.00 0.00%
DYAX $16.54 0.00%
GILD $101.00 0.00%
IRIX $10.20 0.00%
MCK $226.11 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs